Lead therapeutic candidate MOv18 IgE is the world’s first IgE drug to enter clinical trials. Epsilogen, a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, hosted a Key Opinion Leader (KOL) webinar for the...
June 29, 2020 - Events